DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer

被引：0
|
作者：
Li, G. [1 ,2 ]
Su, P. [3 ]
Wang, S. [4 ]
Zhang, Y. [4 ]
Pang, J. [4 ]
Ou, Q. [4 ]
Shao, Y. [4 ]
Yu, H. [5 ]
Wang, X. [1 ,2 ]
机构：
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu, Peoples R China
[2] Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China
[3] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China
[4] Nanjing Geneseeq Technol Inc, Nanjing, Peoples R China
[5] Chengdu Jinniu Dist Peoples Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
DOT1L; Immune checkpoint inhibitors; Next-generation sequencing;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.21-17
引用
收藏
页码：S242 / S242
页数：1
相关论文
共 50 条
  • [21] Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors
    Barlesi, Fabrice
    Tomasini, Pascale
    LANCET ONCOLOGY, 2020, 21 (05): : 607 - 608
  • [22] Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer
    Miyawaki, Taichi
    Kenmotsu, Hirotsugu
    Mori, Keita
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Harada, Hideyuki
    Endo, Masahiro
    Ohde, Yasuhisa
    Takahashi, Kazuhisa
    Takahashi, Toshiaki
    CLINICAL LUNG CANCER, 2020, 21 (05) : E405 - E414
  • [23] Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review
    Ziran Zhao
    Yibo Gao
    Qi Xue
    Shugeng Gao
    Jie He
    Targeted Oncology, 2021, 16 : 425 - 434
  • [24] Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review
    Zhao, Ziran
    Gao, Yibo
    Xue, Qi
    Gao, Shugeng
    He, Jie
    TARGETED ONCOLOGY, 2021, 16 (04) : 425 - 434
  • [25] Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
    Hong, David S.
    Gopal, Ajay K.
    Shoushtari, Alexander N.
    Patel, Sandip P.
    He, Aiwu R.
    Doi, Toshihiko
    Ramalingam, Suresh S.
    Patnaik, Amita
    Sandhu, Shahneen
    Chen, Ying
    Davis, Craig B.
    Fisher, Timothy S.
    Huang, Bo
    Fly, Kolette D.
    Ribas, Antoni
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations
    Zullo, Lodovica
    Rossi, Giovanni
    Dellepiane, Chiara
    Tagliamento, Marco
    Alama, Angela
    Coco, Simona
    Longo, Luca
    Pronzato, Paolo
    De Maria, Andrea
    Genova, Carlo
    IMMUNOTHERAPY, 2021, 13 (06) : 509 - 526
  • [27] Coexistence of Emphysema With Non-small-cell Lung Cancer Predicts the Therapeutic Efficacy of Immune Checkpoint Inhibitors
    Takayama, Yusuke
    Nakamura, Takashi
    Fukushiro, Yuki
    Mishima, Shohei
    Masuda, Ken
    Shoda, Hiroyasu
    IN VIVO, 2021, 35 (01): : 467 - 474
  • [28] EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer
    Fruh, M.
    Peters, S.
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1190 - 1192
  • [29] Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
    Xiaoling Shang
    Wengang Zhang
    Wenfei Han
    Handai Xia
    Ni Liu
    Xiuwen Wang
    Yanguo Liu
    BMC Pulmonary Medicine, 23
  • [30] Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
    Shang, Xiaoling
    Zhang, Wengang
    Han, Wenfei
    Xia, Handai
    Liu, Ni
    Wang, Xiuwen
    Liu, Yanguo
    BMC PULMONARY MEDICINE, 2023, 23 (01)
12345